Our study confirmed that LCC patients treated with upfront anti-EGFR-CHT achieved superior outcomes (ORR and DPR) compared to RCC patients, which is consistent with the literature and reflects previously described differences in the clinical course of cancers arising from different parts of the colon [8]. This evidence concerns the gene EGFR and cancer.